The Relationship of HER2 Copy Number Evaluated by Brightfield Dual In Situ Hybridisation DNA Assay and Pathologic Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer

被引：0
|
作者：
Neville, G. [1 ]
Feeley, L. [1 ]
Bennett, M. W. [1 ]
O'Reilly, S. [1 ]
Corrigan, M. [1 ]
O'Connell, F. [1 ]
Browne, T. J. [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
JOURNAL OF PATHOLOGY | 2017年 / 243卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [31] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Yang, Zheng-Jun
    Xin, Fei
    Chen, Zu-Jin
    Yu, Yue
    Wang, Xin
    Cao, Xu-Chen
    BMC CANCER, 2024, 24 (01)
  • [32] An Appraisal of Clinicopathologic Parameters Associated with Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer
    Rong, Juan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 248 - 248
  • [33] An Appraisal of Clinicopathologic Parameters Associated with Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer
    Rong, Juan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 248 - 248
  • [34] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [35] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245
  • [36] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [37] Dual inhibition of HER2 in breast cancer treatment
    Gnant, Michael
    Steger, Guenther G.
    LANCET, 2012, 379 (9816): : 596 - 598
  • [38] Heterogeneity in treatment response in patients with HER2 positive breast cancer
    Carey, L. A.
    BREAST, 2019, 44 : S5 - S5
  • [39] Heterogeneity in treatment response in patients with HER2 positive breast cancer
    Prat, A.
    BREAST, 2019, 44 : S3 - S4
  • [40] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
12345